The Motley Fool recommends AstraZeneca Plc. The Motley Fool has a disclosure policy ... partly due to the seasonality of FluMist and increased before it is supplied to Sanofi, following a very ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

Additionally, the quality and impact of our scientific research was well recognised this quarter with data for AstraZeneca medicines featuring in an unprecedented five Presidential Plenary sessions at ...

Global pharmaceutical giant, AstraZeneca, has published its views on the recent report published by England’s Chief Medical Officer on the rise in drug-resistant bacteria being a worldwide ...

A variety of medical device innovations and diagnostics have been named by Time as some of the best inventions of 2024.

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through affiliate links at no additional cost to the purchaser.

(Alliance News) - AstraZeneca PLC on Monday welcomed approval in the European Union of Fasenra for the treatment of eosinophilic granulomatosis with polyangiitis. EGPA is a rare, immune-mediated ...

New indication supported by the MANDARA trial, which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids AstraZeneca’s Fasenra (benralizumab) ...

A Covid vaccine compensation scheme could be set up after thousands claimed they have been left disabled as a result of the AstraZeneca jab, The Telegraph has learnt. The Health Secretary is ...

SATURDAY, Oct. 26, 2024 (HealthDay News) -- Now that the U.S. Food and Drug Administration has approved the at-home use of the flu vaccine spray FluMist, how do you know that it's the right choice for ...